Amylin/Takeda combo the latest casualty in obesity war of attrition
This article was originally published in Scrip
Executive Summary
Amylin and Takeda have decided to discontinue the development of the combination therapy for obesity pramlintide plus metreleptin at the Phase II stage, in what they said was a joint decision based on "a commercial reassessment" of the programme.